BMY

Bristol-Myers Squibb
D

BMY

Arincen68/100B

Bristol-Myers Squibb EPS (earnings per share) 1987–2026

Bristol-Myers Squibb's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 1.05 USD, down 2.8% on the same quarter a year before. Bristol-Myers Squibb's diluted earnings per share over the last twelve months were 4.51 USD, up 52.6% on the twelve months before. In fiscal year 2025 they were 3.45 USD, against a loss of 4.41 USD on the year before.

Last updated 12 Nov 2026 · Next report 4 Feb 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 20264.51+52.61%4.52
FY202531 Dec 20253.45—3.46
FY202431 Dec 2024-4.41-214.25%-4.41
FY202331 Dec 20233.86+30.85%3.88
FY202231 Dec 20222.95-5.45%2.97
FY202131 Dec 20213.12—3.15
FY202031 Dec 2020-3.98-298.01%-3.98
FY201931 Dec 20192.01-33.66%2.02
FY201831 Dec 20183.03+396.72%3.03
FY201731 Dec 20170.61-76.98%0.61
FY201631 Dec 20162.65+173.20%2.67
FY201531 Dec 20150.97-19.17%0.97
FY201431 Dec 20141.20-22.08%1.21
FY201331 Dec 20131.54+32.76%1.56
FY201231 Dec 20121.16-46.30%1.17
FY201131 Dec 20112.16+20.00%2.18
FY201031 Dec 20101.80-66.48%1.81
FY200931 Dec 20095.37+104.96%5.38
FY200831 Dec 20082.62+140.37%2.65
FY200731 Dec 20071.09+34.57%1.10
FY200631 Dec 20060.81-46.36%0.81
FY200531 Dec 20051.51+24.79%1.54
FY200431 Dec 20041.21-23.90%1.23
FY200331 Dec 20031.59+55.88%1.60
FY200231 Dec 20021.02-61.80%1.03
FY200131 Dec 20012.67+13.14%2.70
FY200031 Dec 20002.36+14.56%2.40
FY199931 Dec 19992.06+32.90%2.10
FY199831 Dec 19981.55-1.27%1.58
FY199731 Dec 19971.57+12.14%1.61
FY199631 Dec 19961.40+57.30%1.42
FY199531 Dec 19950.89-1.11%0.90
FY199431 Dec 19940.90-5.26%0.90
FY199331 Dec 19930.95-1.04%0.95
FY199231 Dec 19920.96-3.03%0.96
FY199131 Dec 19910.99+17.86%0.99
FY199031 Dec 19900.84+133.33%0.84
FY198931 Dec 19890.36-40.00%0.36
FY198831 Dec 19880.60+20.00%0.60
FY198731 Dec 19870.50—0.50

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Bristol-Myers Squibb's EPS

Source: Financial Modeling PrepVerified against SEC filings